Pentostatin in chronic lymphocytic leukemia

Bibliography

• Ries LAG, Krapcho M, Mariotto A, et al., editors. SEER Cancer Statistics Review, 1975 – 2004. 2007, National Cancer Institute: Bethesda, MD
   Google Scholar
• Doan CA, Wiseman BK, Bouroncle BA. Clinical evaluation of CB 1348 in leukemias and lymphomas. Ann NY Acad Sci 1958;68(3):979-95
   PubMed Web of Science ®Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002;16(6):1015-27
   PubMed Web of Science ®Google Scholar
• Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973;31(3):502-8
   PubMed Web of Science ®Google Scholar
• Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol 1995;6(3):219-35
   PubMed Web of Science ®Google Scholar
• Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985;3(9):1196-201
   PubMed Web of Science ®Google Scholar
• Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988;30(5-6):457-9
   PubMedGoogle Scholar
• Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72(3):1069-73
   PubMed Web of Science ®Google Scholar
• Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2003;121(5):692-702
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991;9(1):44-9
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343(24):1750-7
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885-91
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347(9013):1432-8
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82(6):1695-700
   PubMed Web of Science ®Google Scholar
• Elias L, Stock-Novack D, Head DR, et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a southwest oncology group study. Leukemia 1993;7(3):361-5
   PubMed Web of Science ®Google Scholar
• Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994;8(8):1290-3
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19(5):1414-20
   PubMed Web of Science ®Google Scholar
• Weiss MA, Glenn M, Maslak P, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000;14(9):1577-82
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4070-8
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13(3):570-4
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723-9
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002;3(5):244-50
   PubMedGoogle Scholar
• Brogden RN, Sorkin EM. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993;46(4):652-77
   PubMed Web of Science ®Google Scholar
• Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2(7786):1067-9
   PubMed Web of Science ®Google Scholar
• Hovi T, Smyth JF, Allison AC, Williams SC. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol 1976;23(3):395-403
   PubMed Web of Science ®Google Scholar
• Smyth JF, Harrap KR. Adenosine deaminase activity in leukaemia. Br J Cancer 1975;31(5):544-9
   PubMed Web of Science ®Google Scholar
• Ho DH, Pincus C, Carter CJ, et al. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat Rep 1980;64(4-5):629-33
   PubMedGoogle Scholar
• Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75(2):377-83
   PubMed Web of Science ®Google Scholar
• Venner PM, Glazer RI, Blatt J, et al. Levels of 2′-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res 1981;41(11 Pt 1):4508-11
   PubMed Web of Science ®Google Scholar
• Johnson SA. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet 2000;39(1):5-26
   PubMed Web of Science ®Google Scholar
• Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood 1981;58(1):91-6
   PubMed Web of Science ®Google Scholar
• Poster DS, Penta JS, Bruno S, Macdonald JS. 2′-deoxycoformycin. A new anticancer agent. Cancer Clin Trials 1981;4(2):209-13
   PubMedGoogle Scholar
• Paine RM, Smyth JF, Harrap KR. Biochemical consequences of treatment with the adenosine deaminase inhibitor 2′-deoxycoformycin. Adv Exp Med Biol 1979;122B:365-71
   PubMedGoogle Scholar
• Poplack DG, Sallan SE, Rivera G, et al. Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 1981;41(9 Pt 1):3343-6
   PubMed Web of Science ®Google Scholar
• Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981;57(3):406-17
   PubMed Web of Science ®Google Scholar
• Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989;7(4):433-8
   PubMed Web of Science ®Google Scholar
• Ho AD, Thaler J, Stryckmans P, et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990;82(17):1416-20
   PubMed Web of Science ®Google Scholar
• Johnson SA, Catovsky D, Child JA, et al. Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 1998;16(2):155-60
   PubMed Web of Science ®Google Scholar
• Johnston JB, Verburg L, Shore T, et al. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 1994;8(Suppl 1):S140-3
   PubMed Web of Science ®Google Scholar
• Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003;21(7):1278-84
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24(10):1575-81
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109(2):405-11
   PubMed Web of Science ®Google Scholar
• Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987;316(14):825-30
   PubMed Web of Science ®Google Scholar
• Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989;7(2):168-72
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matutes E, Talavera JG, et al. Long term results with 2′deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl 1):109-13
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96(9):2981-6
   PubMed Web of Science ®Google Scholar
• Grever MR, Bisaccia E, Scarborough DA, et al. An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983;61(2):279-82
   PubMed Web of Science ®Google Scholar
• Greiner D, Olsen EA, Petroni G. Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36(6 Pt 1):950-5
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Giles F, Duvic M, et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an MD Anderson Cancer Center series. Cancer 2004;100(2):342-9
   PubMed Web of Science ®Google Scholar
• Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies – a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999;10(12):1493-8
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23(12):2661-8
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007;25(27):4255-61
   PubMed Web of Science ®Google Scholar
• Ferrajoli A OBS, Wierda W, Lerner S, et al. Treatmnet of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005;46(Suppl 1):S86
   Google Scholar
• Barbara F, Eichhorst RB, Martina Stauch, et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a phase III study of the German CLL Study Group (GCLLSG). Blood 2007;110(11):194a
   Google Scholar
• Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109(11):2291-8
   PubMed Web of Science ®Google Scholar